Gilla Kaplan Sells 14,295 Shares of Tyra Biosciences (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Gilla Kaplan sold 14,295 shares of the company’s stock in a transaction that occurred on Wednesday, March 25th. The stock was sold at an average price of $36.97, for a total value of $528,486.15. Following the transaction, the director directly owned 28,231 shares in the company, valued at approximately $1,043,700.07. This trade represents a 33.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Tyra Biosciences Stock Performance

Shares of Tyra Biosciences stock opened at $36.29 on Monday. The stock has a market capitalization of $1.95 billion, a PE ratio of -18.05 and a beta of 1.06. Tyra Biosciences, Inc. has a 52 week low of $6.42 and a 52 week high of $39.15. The stock has a 50 day moving average price of $32.90 and a two-hundred day moving average price of $23.85.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Monday, March 2nd. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03). Research analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Hedge Funds Weigh In On Tyra Biosciences

A number of hedge funds have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd bought a new position in Tyra Biosciences in the 4th quarter valued at $79,000. Seven Fleet Capital Management LP bought a new stake in shares of Tyra Biosciences during the 4th quarter worth $2,092,000. Invesco Ltd. boosted its holdings in shares of Tyra Biosciences by 734.5% in the 4th quarter. Invesco Ltd. now owns 129,435 shares of the company’s stock worth $3,403,000 after buying an additional 113,925 shares during the last quarter. VARCOV Co. bought a new position in Tyra Biosciences during the fourth quarter valued at about $255,000. Finally, Virtus Investment Advisers LLC grew its position in Tyra Biosciences by 6.7% during the fourth quarter. Virtus Investment Advisers LLC now owns 11,756 shares of the company’s stock valued at $309,000 after buying an additional 741 shares during the period. 84.14% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on TYRA shares. Wall Street Zen lowered shares of Tyra Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, January 24th. Barclays began coverage on shares of Tyra Biosciences in a research report on Tuesday, January 27th. They set an “overweight” rating for the company. Cantor Fitzgerald assumed coverage on shares of Tyra Biosciences in a research report on Tuesday, February 24th. They issued an “overweight” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Wednesday, January 21st. Finally, Jefferies Financial Group boosted their price objective on Tyra Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a report on Tuesday, February 3rd. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Tyra Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.67.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.